This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Conditions

• Heart Failure

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Empagliflozin — DRUG
  Film-coated tablet
• Placebo — DRUG
  Film-coated tablet

Study Details

The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection fraction (LVEF \> 40%). Secondary objectives are to assess Patient-Reported Outcome (PRO)

Key Dates

Start date

Mar 20, 2018

Status verified

Nov 2020

Primary completion

Oct 4, 2019

Completion

Oct 9, 2019

Study Design

Enrollment

315 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Empagliflozin
• Active Comparator: Placebo

Primary Outcome Measure

Change From Baseline to Week 12 in Exercise Capacity as Measured by the Distance Walked in 6 Minutes in Standardised Conditions (6MWTD) [ Time Frame: At baseline and at Week 12 ]

Locations (43)

Find similar trials in Mobile, AL

Related Studies

• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  Recruiting · Medtronic · Birmingham, Alabama
• Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
  Recruiting · UConn Health · Farmington, Connecticut
• Identification of Genomic Predictors of Adverse Events After Cardiac Surgery
  Recruiting · Brigham and Women's Hospital · Boston, Massachusetts
• Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
  Recruiting · Arunark Kolipaka · Columbus, Ohio